InflaRx (IFRX) EBT Margin (2023 - 2026)
InflaRx's (IFRX) quarterly EBT Margin came in at 15889.99% in Q2 2026, up 1553731.0% year-over-year from N/an in Q2 2025, and down 143.3% quarter-over-quarter from 36693.7% in Q4 2025.
Powered by 
Analysis
InflaRx (IFRX) EBT Margin (2023 - 2026) Analysis & Trends
InflaRx has disclosed EBT Margin across 4 years of filings, most recently posting 15889.99% for Q2 2026.
- In Q2 2026, EBT Margin rose 1553731.0% year-over-year to 15889.99%; the TTM figure through Jun 2026 stood at 51192.77% (down 574617.0% YoY), while the FY2025 annual figure was 155540.21%, down 12775840.0% from the prior year.
- EBT Margin came in at 15889.99% for Q2 2026 at InflaRx, down from 36693.7% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 12367345.39% in Q4 2024 to a low of 1916032.98% in Q4 2023.
- Average EBT Margin over 4 years is 916283.25%, with a median of 31427.3% recorded in 2025.
- Year-over-year, EBT Margin soared 1428337837 bps in 2024 and plunged 1233065169 bps in 2025.
- Over 4 years, EBT Margin stood at 1916032.98% in 2023, then surged by 745 bps to 12367345.39% in 2024, then slumped by 100 bps to 36693.7% in 2025, then slumped by 143 bps to 15889.99% in 2026.
- Per Business Quant data, the three most recent EBT Margin figures were 15889.99% in Q2 2026, 36693.7% in Q4 2025, and 37870.38% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -20,427.46% |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn | -15,889.99% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15,889.99% |
| Dec 31, 2025 | 36,693.70% |
| Sep 30, 2025 | -37,870.38% |
| Jun 30, 2025 | -31,427.30% |
| Mar 31, 2025 | -34,706.80% |
| Dec 31, 2024 | 12,367,345.39% |
| Sep 30, 2024 | -11,780.65% |
| Jun 30, 2024 | -228,719.33% |
| Mar 31, 2024 | -32,121.52% |
| Dec 31, 2023 | -1,916,032.98% |
| Sep 30, 2023 | -16,374.41% |